Bohui Innovation(SZ:300318)2023-09-19 09:44Group 1: Company Overview - The company was listed on May 23, 2012, and has two main business segments: inspection and testing services, and blood products [2] - The inspection and testing business has maintained stable revenue in recent years, while blood products have become a key area of development since entering the sector in 2015 [2] Group 2: Blood Plasma Collection - The company currently operates 15 plasma collection stations, with 6 in Yunnan, 2 in Inner Mongolia, and 1 in Shandong, among others [2] - In the first half of 2023, the company collected approximately 202 tons of plasma, with an expectation to exceed 400 tons for the entire year [2] Group 3: Production Capacity and Projects - The designed production capacity for the Yunnan blood product project is 1,500 tons of raw plasma per year, while the Inner Mongolia factory is designed for 800-1,000 tons [3] - The Yunnan project has completed construction and equipment installation, but the official operation date is pending government approval for production qualification [3] Group 4: Product Development and Market Position - The company is developing new products, including "Human Coagulation Factor VIII," which is in clinical stages, and "Human Fibrinogen," which is under research [3] - The company’s blood product revenue is currently lower than industry peers due to processing capacity constraints, with existing facilities operating at full capacity [3]